0001209191-20-020125.txt : 20200318 0001209191-20-020125.hdr.sgml : 20200318 20200318202058 ACCESSION NUMBER: 0001209191-20-020125 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200316 FILED AS OF DATE: 20200318 DATE AS OF CHANGE: 20200318 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Pande Atul CENTRAL INDEX KEY: 0001643071 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37418 FILM NUMBER: 20726162 MAIL ADDRESS: STREET 1: C/O AXOVANT SCIENCES, INC. STREET 2: 1441 BROADWAY, 3RD FLOOR CITY: NEW YORK STATE: NY ZIP: 10018 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Axovant Gene Therapies Ltd. CENTRAL INDEX KEY: 0001636050 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 981333697 FISCAL YEAR END: 0331 BUSINESS ADDRESS: STREET 1: 11-12 ST. JAMES'S SQUARE STREET 2: SUITE 1, 3RD FLOOR CITY: LONDON STATE: X0 ZIP: SW1Y 4LB BUSINESS PHONE: 44 203 318 9708 MAIL ADDRESS: STREET 1: 11 TIMES SQUARE STREET 2: 33RD FLOOR CITY: NEW YORK STATE: NY ZIP: 10036 FORMER COMPANY: FORMER CONFORMED NAME: Axovant Sciences Ltd. DATE OF NAME CHANGE: 20150324 FORMER COMPANY: FORMER CONFORMED NAME: Axovant Sciences, Inc. DATE OF NAME CHANGE: 20150324 FORMER COMPANY: FORMER CONFORMED NAME: Roivant Neurosciences Ltd. DATE OF NAME CHANGE: 20150309 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2020-03-16 0 0001636050 Axovant Gene Therapies Ltd. AXGT 0001643071 Pande Atul C/O AXOVANT GENE THERAPIES LTD. 11 TIMES SQUARE, 33RD FLOOR NEW YORK NY 10036 1 0 0 0 Common Stock 2020-03-16 4 P 0 10000 1.7844 A 13370 I By Atul C. Pande & Patricia A Pande TR DTD 08/24/2017 The reported price in Column 4 is a weighted-average purchase price. These shares were purchased in multiple transactions at prices ranging from $1.77 to $1.82 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Includes 3,370 shares that were previously reported as directly owned. /s/ Alison Haggerty, Attorney-in-Fact 2020-03-18